Grand Pharmaceutical Group Limited (HKG: 0512) announced that its China‑based Phase III clinical trial for TLX591‑CDx (Illuccix, gallium Ga 68 PSMA‑11) achieved positive topline results and met its primary endpoint. The investigational Radiopharmaceutical Drug Conjugate (RDC) for prostate cancer diagnosis is a global‑first diagnostic agent based on radionuclide‑small molecule conjugation technology.
Contents
Regulatory Milestone
| Item | Details |
|---|---|
| Trial Completion | Positive topline results; primary endpoint met |
| Product | TLX591‑CDx (Illuccix) |
| Mechanism | Targets Prostate‑Specific Membrane Antigen (PSMA) |
| Innovation | Global‑first diagnostic RDC for prostate cancer |
| Key Attributes | Internalization, stable activity, short half‑life, tumor permeability, rapid non‑target clearance |
| Indication | Diagnosis of newly diagnosed and recurrent prostate cancer |
Global Commercial Footprint
| Year | Markets/Approvals |
|---|---|
| 2021 | Australia (Nov), United States (Dec) |
| 2022 | Canada (Oct) |
| 2023‑2024 | Expanded indications in US, Australia, Canada for PSMA‑targeted therapy screening |
| 2025 | 21 European/international markets (UK, Germany, France, Italy, Spain, Brazil, Norway) |
| 2026 (Projected) | China NDA submission based on Phase III data |
Market Opportunity & Competitive Landscape
| Metric | Value | Context |
|---|---|---|
| China Prostate Cancer Incidence | ~120,000 new cases (2025) | Growing diagnosis rate; high recurrence risk |
| China RDC Market | ¥2‑3 billion (≈ US$280‑420 M) | Radiopharmaceuticals gaining traction in oncology |
| PSMA‑Targeted Market | $1.2 billion globally (2025) | Dominated by PET/CT imaging agents |
| TLX591‑CDx Peak Sales | ¥500‑800 million (≈ US$70‑112 M) by 2030 | 40‑50% share of China PSMA‑RDC segment |
| Competitive Advantage | First global RDC with proven efficacy across 25+ markets | Regulatory pathway validated; cost vs. PET/CT favorable |
Strategic Implications
- For Grand Pharmaceutical: Phase III success validates proprietary RDC platform; global footprint creates regulatory bridge for China filing; RDC pipeline (diagnostic + therapeutic) positions company in high‑growth radiopharma sector.
- For Patients: PSMA‑targeted imaging improves accuracy of prostate cancer staging vs. conventional imaging; short half‑life reduces radiation exposure; enables selection for PSMA‑targeted radionuclide therapy.
- For Market: China Phase III demonstrates global trial execution capability; massive global approvals support faster NMPA review; RDC platform could expand to other tumor types (e.g., FAP, HER2).
Forward‑Looking Statements
This brief contains forward‑looking statements regarding TLX591‑CDx’s China NDA timeline, market penetration, and regulatory approval. Actual results may differ due to NMPA feedback, competitive responses, or pricing negotiations.-Fineline Info & Tech
